Sentinel lymph node biopsy in melanoma

Matthew T. Hueman, Julie R. Lange*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Sentinel lymph node biopsy (SLNB) for patients with newly diagnosed localized invasive melanoma provides excellent prognostic information and results in improved regional disease control. Prior to the common use of SLNB, regional nodal recurrence was the single most common site of melanoma recurrence, with symptomatic, bulky disease that could be disabling and difficult or impossible to control. With the widespread use of SLNB, regional recurrence of melanoma is much less frequent. Even without clear evidence of improvement in overall survival, the significant and reliable prognostic information and the improved regional control make sentinel node biopsy an important procedure that should be offered routinely to many patients with newly diagnosed melanoma.

Original languageEnglish
Pages (from-to)243-250
Number of pages8
JournalCurrent Treatment Options in Oncology
Issue number4-6
StatePublished - 2008
Externally publishedYes


Dive into the research topics of 'Sentinel lymph node biopsy in melanoma'. Together they form a unique fingerprint.

Cite this